Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial

Summary

The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases from colorectal cancer (CRC).

Timeline

Start

2014-08

Primary completion

2016-12-10

Completion

2016-12-10

Drugs

Indications